AntriaBio’s lead diabetes product candidate, AB101, is a once-a-week injectable basal insulin that is currently in preclinical development. AB101 is to be administered by subcutaneous injection and is intended for use in patients with Type 1 and Type 2 diabetes who require basal insulin for the control of hyperglycemia.

from http://www.antriabio.com/

Patents show all

13Applications6Issued

SEC Filings show all

8-K5610-Q18D910-K6S-11

Contact Information